摘要
目的观察槐耳颗粒联合索拉非尼对原发性肝癌术后复发/转移患者的临床疗效。方法60例原发性肝癌术后复发/转移的患者随机分为对照组和治疗组,每组30例。对照组予索拉非尼单药治疗,治疗组在对照组基础上联合槐耳颗粒辅助治疗。观察2组的客观缓解率(ORR)、疾病控制率(DCR)、1年生存率、无进展生存时间(PFS)和不良反应。结果治疗组和对照组的ORR分别为46.7%和20.0%,DCR分别为76.7%和50.0%,1年生存率分别为60.0%和33.3%,两组比较,P<0.05。治疗组和对照组的PFS分别为(4.77±2.27)个月和(3.57±1.78)个月,P<0.05。治疗期间,治疗组和对照组的不良反应发生率分别为16.7%和33.3%,P<0.05。结论槐耳颗粒联合索拉非尼治疗原发性肝癌术后复发/转移患者的临床疗效好、1年生存率高、PFS得到改善、不良反应发生率低,值得进一步推广应用。
Objective To observe the clinical effect of huaier granule combined with sorafenib on patients with recurrence or metastasis of primary liver cancer after operation.Methods 60 patients with recurrence or metastasis of primary liver cancer after operation were randomly divided into the control group and the treatment group,30 cases in each group.The control group was treated with sorafenib monotherapy,and the treatment group was treated with huaier granule on the basis of the control group.The objective response rate(ORR),disease control rate(DCR),1-year survival rate,progression-free survival time(PFS),and adverse reactions were observed in the 2 groups.Results The ORR of the treatment group and the control group were 46.7%and 20.0%,respectively,and the DCR of the 2 groups were 76.7%and 50.0%,respectively.The 1-year survival rates of the 2 groups were 60.0%and 33.3%,P<0.05.The PFS of the treatment group and the control group were(4.77±2.27)months and(3.57±1.78)months,P<0.05.During the treatment period,the incidence of adverse reactions in the treatment group and the control group were 16.7%and 33.3%,P<0.05.Conclusion Huaier granule combined with sorafenib has good clinical efficacy,high 1-year survival rate,improved PFS and low incidence of adverse reactions in the treatment of recurrence or metastasis of primary hepatocellular carcinoma after operation,which is worthy of further clinical application.
作者
张庆辉
梁艳华
ZHANG Qinghui;LIANG Yanhua(Xuchang Central Hospital Affiliated to Henan University of Science and Technology,Xuchang,461000)
出处
《实用癌症杂志》
2019年第9期1560-1562,共3页
The Practical Journal of Cancer
关键词
原发性肝癌
索拉非尼
槐耳颗粒
无进展生存时间
Primary liver cancer
Sorafenib
Huaier granules
Progression-free survival time
